Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 38: 2318-2321, 1992;
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Deftos, L. J.
Right arrow Articles by Burton, D. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Deftos, L. J.
Right arrow Articles by Burton, D. W.

Clinical Chemistry, Vol 38, 2318-2321, Copyright © 1992 by American Association for Clinical Chemistry

Two-site assays of bone gla protein (osteocalcin) demonstrate immunochemical heterogeneity of the intact molecule

LJ Deftos, RL Wolfert, CS Hill and DW Burton
Department of Medicine, San Diego VA Medical Center, University of California.

We developed a panel of monoclonal antibodies to human bone gla protein (BGP; osteocalcin) peptides that span the linear sequence of the molecule, specifically BGP 1-12 (N-terminal), BGP 15-30 (midregion), and BGP 38-49 (C-terminal). These antibodies were evaluated in various combinations of two-site formats in studies of serum BGP concentrations. For clinical studies, we selected from a panel of antibodies the two most sensitive antibody pairs for the intact molecule (N-C); we also used a polyclonal RIA based on BGP-C. For the two-site format, we used two N-terminal antibodies, 029 and 052, adsorbed to polystyrene beads, and radioiodinated a C-terminal antibody, 663. The standard for each of the assays was purified human BGP. The following BGP serum concentrations (microgram/L, mean +/- SE) were measured with the various assays: by the 029-663 assay, results for normal subjects were 7 +/- 3, for patients with renal failure 25 +/- 8, and for patients with Paget disease 12 +/-4; by the 052-663 assay, the respective results were 22 +/- 4, 44 +/- 12, and 31 +/- 7; by the polyclonal assay, the results were 3 +/- 0.2, 13 +/- 2, and 5 +/- 1. The two intact (N-C) assays were significantly (P < 0.01) correlated (r = 0.94), but their serum values differed by more than twofold in terms of the same BGP standard. The polyclonal assay significantly correlated with each of the intact assays (r = 0.83, 0.77), but it, too, gave different serum values for BGP. These studies demonstrate the immunochemical heterogeneity of circulating BGP, heterogeneity that is manifest even in immunoassays specific for the same region of the molecule.


The following articles in journals at HighWire Press have cited this article:


Home page
 Nephrol Dial TransplantHome page
T. Morishita, M. Nomura, M. Hanaoka, T. Saruta, T. Matsuo, and Y. Tsukamoto
A new assay method that detects only intact osteocalcin. Two-step non-invasive diagnosis to predict adynamic bone disease in haemodialysed patients
Nephrol. Dial. Transplant., May 1, 2000; 15(5): 659 - 667.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
S.-M. Kakonen, J. Hellman, M. Karp, P. Laaksonen, K. J. Obrant, H. K. Vaananen, T. Lovgren, and K. Pettersson
Development and Evaluation of Three Immunofluorometric Assays That Measure Different Forms of Osteocalcin in Serum
Clin. Chem., March 1, 2000; 46(3): 332 - 337.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1992 by the American Association for Clinical Chemistry.